|
1
|
Curcumin: the story so far.
|
Eur J Cancer
|
2005
|
4.17
|
|
2
|
Structure and function of heparan sulphate proteoglycans.
|
Biochem J
|
1986
|
2.78
|
|
3
|
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.
|
Clin Cancer Res
|
2001
|
2.69
|
|
4
|
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
|
Br J Cancer
|
1999
|
2.22
|
|
5
|
Molecular prognostic markers in pancreatic cancer: a systematic review.
|
Eur J Cancer
|
2005
|
2.20
|
|
6
|
Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production.
|
Cancer Res
|
2001
|
2.05
|
|
7
|
Gemcitabine--a major advance?
|
Ann Oncol
|
1998
|
2.05
|
|
8
|
Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration.
|
Br J Cancer
|
2004
|
1.97
|
|
9
|
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
|
Ann Oncol
|
2005
|
1.57
|
|
10
|
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
|
Br J Cancer
|
2000
|
1.57
|
|
11
|
Role of inflammation in pancreatic carcinogenesis and the implications for future therapy.
|
Pancreatology
|
2005
|
1.47
|
|
12
|
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease.
|
Eur J Cancer
|
2000
|
1.43
|
|
13
|
Prognosis of isolated seizures in adult life.
|
Br Med J (Clin Res Ed)
|
1981
|
1.43
|
|
14
|
Latest trends in cancer incidence among UK South Asians in Leicester.
|
Br J Cancer
|
2003
|
1.42
|
|
15
|
Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene.
|
Br J Cancer
|
2004
|
1.40
|
|
16
|
Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies.
|
Eur J Cancer
|
2005
|
1.19
|
|
17
|
Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels.
|
Clin Cancer Res
|
2001
|
1.14
|
|
18
|
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.
|
Br J Cancer
|
2006
|
1.12
|
|
19
|
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study.
|
Eur J Cancer
|
2000
|
1.12
|
|
20
|
Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity.
|
Br J Cancer
|
2003
|
1.11
|
|
21
|
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma.
|
Br J Cancer
|
2003
|
1.08
|
|
22
|
Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases.
|
Eur J Cancer
|
2008
|
1.07
|
|
23
|
Angiogenesis and non-small cell lung cancer.
|
Lung Cancer
|
2000
|
1.06
|
|
24
|
Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics.
|
Cancer Prev Res (Phila)
|
2011
|
1.06
|
|
25
|
Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study.
|
J Clin Oncol
|
1999
|
1.05
|
|
26
|
Identification of an extended N-acetylated sequence adjacent to the protein-linkage region of fibroblast heparan sulphate.
|
Biochem J
|
1987
|
1.03
|
|
27
|
Cancer chemoprevention by dietary constituents: a tale of failure and promise.
|
Lancet Oncol
|
2001
|
1.02
|
|
28
|
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
|
Clin Cancer Res
|
2001
|
1.02
|
|
29
|
Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells.
|
Carcinogenesis
|
2001
|
1.00
|
|
30
|
Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow.
|
Blood
|
1996
|
0.99
|
|
31
|
Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention.
|
Eur J Cancer
|
2003
|
0.98
|
|
32
|
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.
|
Eur J Cancer
|
2006
|
0.98
|
|
33
|
Angiogenesis as a biomarker and target in cancer chemoprevention.
|
Lancet Oncol
|
2001
|
0.97
|
|
34
|
Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer.
|
Lung Cancer
|
2000
|
0.96
|
|
35
|
Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
|
Br J Cancer
|
1989
|
0.96
|
|
36
|
Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
|
Semin Oncol
|
1998
|
0.95
|
|
37
|
Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis.
|
Br J Cancer
|
2007
|
0.94
|
|
38
|
Phase I clinical trial of methylene dimethane sulfonate.
|
Cancer Treat Rep
|
1987
|
0.93
|
|
39
|
Differences in attitudes between patients with primary colorectal cancer and patients with secondary colorectal cancer: is it reflected in their willingness to participate in drug trials?
|
Eur J Cancer Care (Engl)
|
2005
|
0.93
|
|
40
|
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.
|
Thorax
|
1999
|
0.90
|
|
41
|
A prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tract.
|
Eur J Cancer Clin Oncol
|
1985
|
0.90
|
|
42
|
Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer.
|
Cancer
|
1985
|
0.89
|
|
43
|
A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma.
|
Eur J Cancer Clin Oncol
|
1984
|
0.89
|
|
44
|
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.
|
Br J Cancer
|
2002
|
0.89
|
|
45
|
Chondroitin sulphate proteoglycan production by NK cells and T cells: effects of xylosides on proliferation and cytotoxic function.
|
Immunology
|
1988
|
0.89
|
|
46
|
A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome.
|
Pancreatology
|
2009
|
0.88
|
|
47
|
High-grade non-Hodgkin's lymphoma complicating polypoid nodular lymphoid hyperplasia and multiple lymphomatous polyposis of the intestine.
|
Histopathology
|
1989
|
0.88
|
|
48
|
The role of chemotherapy in the treatment of adult soft tissue sarcomas.
|
Oncology
|
1999
|
0.87
|
|
49
|
Vascular endothelial growth factor (VEGF) inhibition by small molecules.
|
J Chemother
|
2004
|
0.86
|
|
50
|
Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents.
|
Cancer Epidemiol Biomarkers Prev
|
2001
|
0.86
|
|
51
|
Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study.
|
Eur J Cancer
|
1990
|
0.86
|
|
52
|
Angiogenesis of gastrointestinal tumours and their metastases--a target for intervention?
|
Eur J Cancer
|
2004
|
0.86
|
|
53
|
Assessment of a patient consultation questionnaire-based scoring system for stratification of outpatient risk of colorectal cancer.
|
Br J Surg
|
2008
|
0.85
|
|
54
|
ErbB receptors: possible therapeutic targets in prostate cancer?
|
BJU Int
|
2003
|
0.84
|
|
55
|
A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group.
|
Br J Cancer
|
1984
|
0.84
|
|
56
|
Somatostatin, its receptors and analogs, in lung cancer.
|
Chemotherapy
|
2001
|
0.83
|
|
57
|
Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents.
|
Eur J Cancer
|
2001
|
0.82
|
|
58
|
Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse.
|
Invest New Drugs
|
2006
|
0.81
|
|
59
|
Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: modification by dietary curcumin and implications for clinical trials.
|
Eur J Cancer
|
2006
|
0.81
|
|
60
|
A phase II study of caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2001
|
0.81
|
|
61
|
Involving patients in treatment decisions: can we learn from clinical trials?
|
Clin Oncol (R Coll Radiol)
|
2001
|
0.80
|
|
62
|
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.
|
Ann Diagn Pathol
|
2000
|
0.80
|
|
63
|
Growth-inhibitory and cell cycle-arresting properties of the rice bran constituent tricin in human-derived breast cancer cells in vitro and in nude mice in vivo.
|
Br J Cancer
|
2004
|
0.80
|
|
64
|
Concomitant chemoradiotherapy for muscle-invasive bladder cancer: the way forward for bladder preservation?
|
Clin Oncol (R Coll Radiol)
|
2005
|
0.79
|
|
65
|
A review of phase III clinical trials of prostate cancer chemoprevention.
|
Ann R Coll Surg Engl
|
2007
|
0.79
|
|
66
|
Recombinant human granulocyte macrophage colony-stimulating factor: current status of clinical trials and potential future applications.
|
Anticancer Drugs
|
1991
|
0.79
|
|
67
|
Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue.
|
Br J Cancer
|
1994
|
0.78
|
|
68
|
Ifosfamide by bolus as treatment for advanced non-small cell lung cancer.
|
Cancer Chemother Pharmacol
|
1986
|
0.78
|
|
69
|
Plasma free iron and chemotherapy toxicity.
|
Lancet
|
1996
|
0.78
|
|
70
|
Etoposide infusions for treatment of metastatic lung cancer.
|
Cancer Treat Rep
|
1984
|
0.77
|
|
71
|
Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors.
|
Expert Rev Anticancer Ther
|
2001
|
0.77
|
|
72
|
Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup.
|
J Clin Oncol
|
1994
|
0.77
|
|
73
|
Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
|
Invest New Drugs
|
1995
|
0.77
|
|
74
|
Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
|
Eur J Cancer
|
1990
|
0.77
|
|
75
|
CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity.
|
J Clin Oncol
|
1996
|
0.77
|
|
76
|
Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?
|
Pathol Oncol Res
|
2000
|
0.76
|
|
77
|
The role of vindesine in oncology--recommendations after 10 years' experience.
|
Anticancer Drugs
|
1995
|
0.76
|
|
78
|
Growth factor-assisted chemotherapy--the Manchester experience.
|
Ciba Found Symp
|
1990
|
0.76
|
|
79
|
Changing trends in the presentation of colorectal liver metastases in a single hepatobiliary tertiary referral centre over fourteen years.
|
Eur J Surg Oncol
|
2013
|
0.76
|
|
80
|
Contrasting effects of rh-MIP-1 alpha and TGF-beta 1 on chronic myeloid leukemia progenitors in vitro.
|
Stem Cells
|
1993
|
0.76
|
|
81
|
The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas.
|
Crit Rev Oncol Hematol
|
1998
|
0.76
|
|
82
|
Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.
|
Expert Opin Emerg Drugs
|
2001
|
0.76
|
|
83
|
Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group.
|
Clin Oncol (R Coll Radiol)
|
1998
|
0.75
|
|
84
|
Efficacy of thymostimulin.
|
Lancet
|
1994
|
0.75
|
|
85
|
Familiar drugs may prevent cancer.
|
Postgrad Med J
|
2001
|
0.75
|
|
86
|
The promise of improved drug delivery.
|
Clin Sci (Lond)
|
1999
|
0.75
|
|
87
|
Chemotherapy for upper gastrointestinal tumours.
|
Postgrad Med J
|
2000
|
0.75
|
|
88
|
A phase II study of cyclophosphamide as a 24-hr infusion in advanced non-small cell lung cancer.
|
Eur J Cancer Clin Oncol
|
1986
|
0.75
|
|
89
|
Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide.
|
Cancer Treat Rep
|
1985
|
0.75
|
|
90
|
Nephrogenic diabetes insipidus following high dose epirubicin chemotherapy for metastatic soft tissue sarcoma.
|
Eur J Cancer
|
1995
|
0.75
|
|
91
|
Chemotherapy for metastatic soft tissue sarcomas.
|
Cancer Treat Res
|
1997
|
0.75
|
|
92
|
The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon.
|
Eur J Cancer
|
1991
|
0.75
|
|
93
|
Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group.
|
Eur J Cancer
|
1992
|
0.75
|
|
94
|
A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
|
Eur J Cancer
|
1995
|
0.75
|
|
95
|
High grade soft tissue sarcoma.
|
Ann Oncol
|
1993
|
0.75
|
|
96
|
Toxic megacolon: remember cytomegalovirus.
|
Hosp Med
|
2001
|
0.75
|
|
97
|
Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.
|
Cancer Chemother Pharmacol
|
2001
|
0.75
|
|
98
|
Ifosfamide, carboplatin and etoposide for good prognosis small cell lung cancer: are four courses inadequate? West of Scotland Lung Cancer Group.
|
Eur J Cancer
|
1995
|
0.75
|
|
99
|
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
|
Eur J Cancer
|
1994
|
0.75
|
|
100
|
Efficient isolation of human CD34 positive hemopoietic progenitor cells by immune panninga.
|
Stem Cells
|
1994
|
0.75
|
|
101
|
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
|
Semin Oncol
|
1992
|
0.75
|